Novartis (NVS) Said in Talks to Buy Amneal Pharma - Bloomberg
- S&P 500 closes higher to secure strongest Q1 since 2019
- UBS sees 5 warnings signals on semiconductor chip stocks
- US consumer sentiment tops estimates in March to hit nearly 3-yr high, UMich says
- Reddit (RDDT) stock continues to slide as short-sellers eye stock
- Estée Lauder (EL) climbs as BofA upgrades to Buy on profit recovery expectations
- AMC Entertainment (AMC) enters into an equity distribution agreement
- Kerrisdale Capital is short Microstrategy (MSTR), long bitcoin
- Discover Financial Services (DFS) Announces CEO Resignation
- Intuitive Machines (LUNR) Files for $300M Share Offering, 160M Share Offering by Selling Stockholders
- AMC Entertainment (AMC) Enters $250M ATM Agreement
Novartis (NVS) Announces AMG 334 Phase 3 Met Primary Endpoint as Migraine Treatment
November 16, 2016 4:35 PM ESTNovartis (NYSE: NVS) announced positive topline results from the global Phase III STRIVE study, evaluating the efficacy and safety of the fully human monoclonal antibody AMG 334 (erenumab) in episodic migraine prevention. Once-monthly subcutaneous AMG 334 was evaluated at 70mg and 140mg doses, with both doses meeting the study's primary endpoint, demonstrating a statistically significant reduction from baseline in mean monthly migraine days at six months versus placebo.[1] AMG 334 is specifically designed to target and block the Calcitonin Gene-Related Peptide (CGRP) receptor that is believed to have a critical role in mediating the incapacitating... More